You are here:
Innovative financing mechanism accelerates global roll out of vaccine against world’s leading cause of child deaths
Pneumococcal vaccines are new, complex vaccines that would normally reach low-income countries 10-15 years after their introduction in industrialised countries.
Thanks to the pneumococcal Advance Market Commitment, children in 50 Gavi-eligible countries are being immunised against the main cause of pneumonia today.
The 2015 Pneumococcal AMC Annual Report gives an overview of the activities linked to the implementation of the pilot Advance Market Commitment from 1 January to 31 December 2015.
It was developed by the AMC Secretariat at Gavi, in collaboration with the World Bank and UNICEF’s Supply Division, and was approved by the Independent Assessment Committee on 1 April 2016.
View previous Annual Reports: 2014-2015 | 2013-2014 | 2012-2013 | 2011-2012 | 2010-2011 | 2009-2010
If you represent a vaccine manufacturer and are interested in participating in the pneumococcal AMC, this section explains how to make your offer.
Suppliers must sign a registration agreement relating to the AMC terms and conditions.
UNICEF issues Calls for Supply Offers following the publication of the Strategic Demand Forecast.
Ghana launches two new vaccines at once
Vaccine brings hope to parents in Yemen
Pakistan tackles top child killer - Pneumonia
Innovative mechanism makes vaccines available for children in developing countries at the right price, in the right quantity and at the right time.
Step by step guide to the method behind the AMC mechanism linking donors, the World Bank, WHO, UNICEF and developing country governments.
The pneumo AMC does not have a separate application procedure. Countries should apply for Gavi pneumococcal vaccine support in the usual way.
Concerned about the misuse of Gavi resources? Report it now.
© Gavi 2017
modal window here